350 related articles for article (PubMed ID: 21677539)
21. N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer.
Pflueger D; Rickman DS; Sboner A; Perner S; LaFargue CJ; Svensson MA; Moss BJ; Kitabayashi N; Pan Y; de la Taille A; Kuefer R; Tewari AK; Demichelis F; Chee MS; Gerstein MB; Rubin MA
Neoplasia; 2009 Aug; 11(8):804-11. PubMed ID: 19649210
[TBL] [Abstract][Full Text] [Related]
22. PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade.
Yoshimoto M; Ding K; Sweet JM; Ludkovski O; Trottier G; Song KS; Joshua AM; Fleshner NE; Squire JA; Evans AJ
Mod Pathol; 2013 Mar; 26(3):435-47. PubMed ID: 23018874
[TBL] [Abstract][Full Text] [Related]
23. TMPRSS2-ERG rearrangement in dominant anterior prostatic tumours: incidence and correlation with ERG immunohistochemistry.
Gopalan A; Leversha MA; Dudas ME; Maschino AC; Chang J; Al-Ahmadie HA; Chen YB; Tickoo SK; Reuter VE; Fine SW
Histopathology; 2013 Aug; 63(2):279-86. PubMed ID: 23701505
[TBL] [Abstract][Full Text] [Related]
24. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement.
Yoshimoto M; Joshua AM; Chilton-Macneill S; Bayani J; Selvarajah S; Evans AJ; Zielenska M; Squire JA
Neoplasia; 2006 Jun; 8(6):465-9. PubMed ID: 16820092
[TBL] [Abstract][Full Text] [Related]
25. ERG gene rearrangement status in prostate cancer detected by immunohistochemistry.
Falzarano SM; Zhou M; Carver P; Tsuzuki T; Simmerman K; He H; Magi-Galluzzi C
Virchows Arch; 2011 Oct; 459(4):441-7. PubMed ID: 21773753
[TBL] [Abstract][Full Text] [Related]
26. TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients.
Magi-Galluzzi C; Tsusuki T; Elson P; Simmerman K; LaFargue C; Esgueva R; Klein E; Rubin MA; Zhou M
Prostate; 2011 Apr; 71(5):489-97. PubMed ID: 20878952
[TBL] [Abstract][Full Text] [Related]
27. Clinical applications of novel ERG immunohistochemistry in prostate cancer diagnosis and management.
Shah RB
Adv Anat Pathol; 2013 Mar; 20(2):117-24. PubMed ID: 23399797
[TBL] [Abstract][Full Text] [Related]
28. TMPRSS2-ERG fusion is frequently observed in Gleason pattern 3 prostate cancer in a Canadian cohort.
Darnel AD; Lafargue CJ; Vollmer RT; Corcos J; Bismar TA
Cancer Biol Ther; 2009 Jan; 8(2):125-30. PubMed ID: 19029822
[TBL] [Abstract][Full Text] [Related]
29. Cysteine-rich secretory protein-3 (CRISP3) is strongly up-regulated in prostate carcinomas with the TMPRSS2-ERG fusion gene.
Ribeiro FR; Paulo P; Costa VL; Barros-Silva JD; Ramalho-Carvalho J; Jerónimo C; Henrique R; Lind GE; Skotheim RI; Lothe RA; Teixeira MR
PLoS One; 2011; 6(7):e22317. PubMed ID: 21814574
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical evaluation of TMPRSS2-ERG gene fusion in adenosis of the prostate.
Green WM; Hicks JL; De Marzo A; Illei PP; Epstein JI
Hum Pathol; 2013 Sep; 44(9):1895-901. PubMed ID: 23664537
[TBL] [Abstract][Full Text] [Related]
31. The role of TMPRSS2:ERG in molecular stratification of PCa and its association with tumor aggressiveness: a study in Brazilian patients.
Eguchi FC; Faria EF; Scapulatempo Neto C; Longatto-Filho A; Zanardo-Oliveira C; Taboga SR; Campos SG
Sci Rep; 2014 Jul; 4():5640. PubMed ID: 25007891
[TBL] [Abstract][Full Text] [Related]
32. TMPRSS2:ERG fusion gene occurs less frequently in Chinese patients with prostate cancer.
Jiang H; Mao X; Huang X; Zhao J; Wang L; Xu J; Zhang H; Lu Y; Yu Y
Tumour Biol; 2016 Sep; 37(9):12397-12402. PubMed ID: 27320318
[TBL] [Abstract][Full Text] [Related]
33. TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling.
Brase JC; Johannes M; Mannsperger H; Fälth M; Metzger J; Kacprzyk LA; Andrasiuk T; Gade S; Meister M; Sirma H; Sauter G; Simon R; Schlomm T; Beissbarth T; Korf U; Kuner R; Sültmann H
BMC Cancer; 2011 Dec; 11():507. PubMed ID: 22142399
[TBL] [Abstract][Full Text] [Related]
34. ERG protein expression over time: from diagnostic biopsies to radical prostatectomy specimens in clinically localised prostate cancer.
Berg KD; Brasso K; Thomsen FB; Røder MA; Holten-Rossing H; Toft BG; Iversen P; Vainer B
J Clin Pathol; 2015 Oct; 68(10):788-94. PubMed ID: 26060265
[TBL] [Abstract][Full Text] [Related]
35. Heterogeneity and chronology of 6q15 deletion and ERG-fusion in prostate cancer.
Kluth M; Meyer D; Krohn A; Freudenthaler F; Bauer M; Salomon G; Heinzer H; Michl U; Steurer S; Simon R; Sauter G; Schlomm T; Minner S
Oncotarget; 2016 Jan; 7(4):3897-904. PubMed ID: 26684029
[TBL] [Abstract][Full Text] [Related]
36. TMPRSS2:ETS fusions and clinicopathologic characteristics of prostate cancer patients from Eastern China.
Dong J; Xiao L; Sheng L; Xu J; Sun ZQ
Asian Pac J Cancer Prev; 2014; 15(7):3099-103. PubMed ID: 24815454
[TBL] [Abstract][Full Text] [Related]
37. Relevance of cohort design for studying the frequency of the ERG rearrangement in prostate cancer.
Braun M; Scheble VJ; Menon R; Scharf G; Wilbertz T; Petersen K; Beschorner C; Reischl M; Kuefer R; Schilling D; Stenzl A; Kristiansen G; Rubin MA; Fend F; Perner S
Histopathology; 2011 Jun; 58(7):1028-36. PubMed ID: 21707704
[TBL] [Abstract][Full Text] [Related]
38. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.
Mosquera JM; Mehra R; Regan MM; Perner S; Genega EM; Bueti G; Shah RB; Gaston S; Tomlins SA; Wei JT; Kearney MC; Johnson LA; Tang JM; Chinnaiyan AM; Rubin MA; Sanda MG
Clin Cancer Res; 2009 Jul; 15(14):4706-11. PubMed ID: 19584163
[TBL] [Abstract][Full Text] [Related]
39. Expression of steroid and peptide hormone receptors, metabolic enzymes and EMT-related genes in prostate tumors in relation to the presence of the TMPRSS2/ERG fusion.
Gerashchenko GV; Mevs LV; Chashchina LI; Pikul MV; Gryzodub OP; Stakhovsky EO; Kashuba VI
Exp Oncol; 2018 Jun; 40(2):101-108. PubMed ID: 29949537
[TBL] [Abstract][Full Text] [Related]
40. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
